share_log

百利天恒(688506.SH):“BL-M07D1+PD-1/PD-L1 单抗±化疗”及“BL-M07D1+帕妥珠单抗±化疗”获得 II 期临床试验批准通知书

Baili Tianheng (688506.SH): “BL-M07D1+PD-1/PD-L1 monoclonal antibody ± chemotherapy” and “BL-M07D1+ pertuzumab ± chemotherapy” obtained approval notice for phase II clinical trials

Gelonghui Finance ·  Apr 2 05:48

Gelonghui, April 2 | Baili Tianheng (688506.SH) announced that the combined drugs “BL-M07D1+PD-1/PD-L1 monoclonal antibody ± chemotherapy” and “BL-M07D1+ pertuzumab ± chemotherapy” related to the innovative biopharmaceutical BL-M07D1 developed by the company have recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA). BL-M07D1 is an ADC drug targeting HER2. Its indications are solid tumors such as breast cancer and stomach cancer.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment